Nabumetone |
|
I |
DEC / 13 |
Nadolol or its salts |
|
I |
DEC / 13 |
Nadroparin or its salts |
|
I |
DEC / 13 |
Nafarelin or its salts or derivatives |
Including but not limited to Nafarelin acetate.
|
I |
DEC / 13 |
Nafcillin or its salts or derivatives |
For veterinary use
|
I |
DEC / 13 |
Nalbuphine and any salt thereofC |
|
I |
JUN / 02 |
Nalidixic acid |
|
I |
DEC / 13 |
Nalmefene or its salts |
|
I |
DEC / 13 |
Naloxegol or its salts |
including but not limited to naloxegol oxalate
|
I |
JUN / 15 |
Naloxone hydrochloride injection, |
when indicated for emergency use for opioid overdose
Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.
|
II |
FEB / 17 |
Naloxone hydrochloride nasal spray, |
when indicated for emergency use for opioid overdose
Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.
|
II |
FEB / 17 |
Naloxone or its salts |
including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose
|
I |
FEB / 17 |
Naltrexone or its salts |
|
I |
DEC / 13 |
Naphazoline and its salts |
in nasal preparations for pediatric use |
II |
SEP / 98 |
Naphazoline and its salts. |
in nasal preparations for adult use and in ophthalmic products |
U |
|
Naproxen or its salts |
Except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base).
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
I |
MAR / 15 |
Naproxen or its salts.. |
In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less.
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
U |
MAR / 15 |
Naproxen or its salts.. |
In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base.
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
III |
MAR / 15 |
Naratriptan or its salts |
|
I |
DEC / 13 |
Natalizumab |
|
I |
DEC / 13 |
Nateglinide or its salts or derivatives |
|
I |
DEC / 13 |
Nebivolol or its salts or derivatives |
|
I |
DEC / 13 |
Necitumumab |
|
I |
APR / 17 |
Nedocromil or its salts |
|
I |
DEC / 13 |
Nefazodone or its salts |
|
I |
DEC / 13 |
Nelarabine |
|
I |
DEC / 13 |
Nelfinavir or its salts |
|
I |
DEC / 13 |
Neocinchophen or its salts |
|
I |
DEC / 13 |
Neomycin or its salts or derivatives |
Including but not limited to: Paromomycin sulfate (for veterinary use)
|
I |
DEC / 18 |
Neostigmine salts |
|
I |
DEC / 13 |
Nepafenac |
|
I |
DEC / 13 |
Neratinib or its salts |
|
I |
OCT / 19 |
Nesiritide or its salts |
|
I |
DEC / 13 |
Netupitant |
|
I |
DEC / 17 |
Nevirapine or its salts |
|
I |
DEC / 13 |
Niacin (nicotinic acid) |
in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose
|
II |
MAR / 10 |
Nialamide or its salts |
|
I |
DEC / 13 |
Nicarbazin |
For human use
|
I |
DEC / 13 |
Nicardipine or its salts |
|
I |
DEC / 13 |
Nicotine or its salts |
For human use - EXCEPT: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered into the oral cavity by means of a non-active device (one that operates on energy generated by the human body or by gravity) that delivers 4 mg or less of nicotine per dose for buccal absorption; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit).
|
I |
AUG / 18 |
Nicotine or its salts |
For veterinary use.
|
I |
DEC / 13 |
Nicotinic acid |
For human use - when sold in: (a) a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 milligrams per dosage unit or per daily dose.
|
I |
DEC / 13 |
Nicotinyl-tartrate |
|
I |
SEP / 98 |
Nifedipine |
|
I |
DEC / 13 |
Nikethamide |
|
I |
SEP / 98 |
Nilotinib or its salts |
|
I |
DEC / 13 |
Nilutamide |
|
I |
DEC / 13 |
Nimodipine or its salts |
|
I |
DEC / 13 |
Nintedanib or its salts |
|
I |
AUG / 15 |
Niraparib or its salts |
|
I |
OCT / 19 |
Nitisinone |
|
I |
NOV / 16 |
Nitric oxide |
|
I |
DEC / 13 |
Nitrofurantoin or its salts |
For human use.
|
I |
DEC / 13 |
Nitroglycerin |
Except for sublingual immediate release dosage forms.
|
I |
SEP / 98 |
Nitroglycerin. |
sublingual immediate release dosage forms |
II |
SEP / 98 |
Nitroscanate |
|
I |
DEC / 13 |
Nivolumab |
|
I |
JAN / 16 |
Nizatidine and its saltsNR |
When sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.*
|
I |
SEP / 98 |
Nizatidine or its salts |
Except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.
|
I |
DEC / 13 |
Nomifensine or its salts |
|
I |
DEC / 13 |
Norepinephrine and its salts |
levarterenol, noradrenaline |
II |
SEP / 98 |
Norfloxacin |
|
I |
DEC / 13 |
Nortriptyline or its salts |
|
I |
DEC / 13 |
Novobiocin or its salts or derivatives |
For human use.
|
I |
DEC / 13 |
Nusinersen |
|
I |
AUG / 17 |
Nylidrin or its salts |
|
I |
DEC / 13 |
Nystatin and its salts and derivatives. |
in topical preparations for use on the skin |
III |
SEP / 98 |
Nystatin or its salts or derivatives |
For human use - except preparations for topical use on the skin.
|
I |
DEC / 13 |